{"nctId":"NCT01047683","briefTitle":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","startDateStruct":{"date":"2009-12"},"conditions":["Hypertriglyceridemia"],"count":229,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"AMR101 (ethyl icosapentate) - 2 g/day","type":"EXPERIMENTAL","interventionNames":["Drug: AMR101 (ethyl icosapentate) - 2 g/day"]},{"label":"AMR101 (ethyl icosapentate) - 4 g/day","type":"EXPERIMENTAL","interventionNames":["Drug: AMR101 (ethyl icosapentate) - 4 g/day"]}],"interventions":[{"name":"AMR101 (ethyl icosapentate) - 4 g/day","otherNames":["VASCEPA® (icosapent ethyl)"]},{"name":"AMR101 (ethyl icosapentate) - 2 g/day","otherNames":["VASCEPA® (icosapent ethyl)"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women, ages \\>18\n* Fasting triglyceride ≥500 mg/dL and ≤2000 mg/dL\n* Provide written informed consent and authorization for protected health information disclosure\n\nExclusion Criteria:\n\n* Women who are pregnant or lactating, or planning to become pregnant\n* Use of non-statin lipid-altering drugs which cannot be stopped including fibrates, niacin, fish oil and other products containing omega-3 fatty acids or other dietary supplements with potential lipid-altering effects\n* History of pancreatitis\n* History of bariatric surgery or currently on weight loss drugs\n* Uncontrolled hypertension (BP \\> 160/100)\n* HIV infection or on treatment with HIV-protease inhibitors, cyclophosphamide,or isotretinoin\n* Consumption of more than 2 alcoholic beverages per day\n* History of cancers (except if been disease free for \\>5 years OR history was basal or squamous cell skin cancer)\n* Participation in another clinical trial involving an investigational agent in the last 30 days\n* Other parameters will be assessed at the study center to ensure eligibility for this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect","description":"Median percent change from baseline to Week 12 in fasting serum triglyceride levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.0","spread":null},{"groupId":"OG001","value":"-26.6","spread":null},{"groupId":"OG002","value":"9.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Very Low-density Lipoprotein Cholesterol Levels","description":"Median percent change from baseline to Week 12 in serum very low-density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"-19.5","spread":null},{"groupId":"OG002","value":"13.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Lipoprotein-associated Phospholipase A2 Levels","description":"Median percent change from baseline to Week 12 in serum Lipoprotein-associated Phospholipase A2 levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":null},{"groupId":"OG001","value":"-17.1","spread":null},{"groupId":"OG002","value":"-2.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Group in Apolipoprotein B Levels","description":"Median in percent change from baseline to Week 12 in serum Apolipoprotein B levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"-3.8","spread":null},{"groupId":"OG002","value":"4.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Low-density Lipoprotein Cholesterol Levels","description":"Median percent change from baseline to Week 12 in serum low density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":null},{"groupId":"OG001","value":"-4.5","spread":null},{"groupId":"OG002","value":"-3.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Non-High-Density Lipoprotein Cholesterol Levels","description":"Median percent change from baseline to Week 12 in serum non-high density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"-7.7","spread":null},{"groupId":"OG002","value":"7.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":76},"commonTop":["Diarrhea","Nausea","Eructation"]}}}